Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1^st June 2022. Frequently Asked Questions (FAQs) relating to access and use of the Online PBS Authorities system is also attached.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website. 

Paroxysmal nocturnal haemoglobinuria

Ravulizumab (Ultomiris®) & eculizumab (Soliris®) housekeeping updates to existing listing for the treatment of paroxysmal nocturnal haemoglobinuria. Authority applications for initial and continuing treatment can be made in writing.

Cystic fibrosis

Elexacaftor 100 mg with tezacaftor 50 mg and ivacaftor 75 mg and 28 tablets of ivacaftor 150 mg (Trikafta®) housekeeping updates to existing listing for the treatment of cystic fibrosis. Authority applications for initial and continuing treatment can be made in writing.

Non-radiographic axial spondyloarthritis

The Grandfather clause for secukinumab (Cosentyx®) for the treatment of non-radiographic axial spondyloarthritis has been removed.

Locally advanced or metastatic breast cancer

The Grandfather clause for Ribociclib (Kisqali®) for the treatment of locally advanced or metastatic breast cancer has been removed.

Prostate cancer

Olaparib (Lynparza®) 100 mg & 150 mg tablet housekeeping updates to existing listings for the treatment of prostate cancer. Authority applications for initial and continuing treatment can be made either in real time using the Online PBS Authorities system or by telephone.

Non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis (Wegener’s granulomatosis), microscopic polyangiitis

Rituximab (Ruxience®) 100 mg in 10 ml & 500 mg in 50 ml I.V. infusion biosimilar is now listed on the PBS for treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis (Wegener’s granulomatosis), microscopic polyangiitis.

1 June 2022 delisted PBS listings

There are no delisting’s for June 2022.

Selecting the correct restriction in the Online PBS Authorities system

Balance of Supply (BoS) restrictions are available through the Online PBS Authorities system. New questions and answers (Q&As) have been applied against BoS restrictions for multiple medicines listed on the PBS for multiple Authority Required (Written) programs to ensure prescribers are selecting the correct restriction and treatment phase to determine their patient’s eligibility. These Q&As will also ensure prescribers are using the correct authority submission channel for the required treatment phase to avoid post compliance activities.

To learn more about these updates, please contact Services Australia directly.

At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.

Follow our LinkedIn and Facebook pages for more information.